Draper Asset Management LLC Has $769,000 Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Draper Asset Management LLC boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 39.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,565 shares of the medical equipment provider’s stock after purchasing an additional 440 shares during the quarter. Intuitive Surgical comprises 0.6% of Draper Asset Management LLC’s investment portfolio, making the stock its 14th biggest position. Draper Asset Management LLC’s holdings in Intuitive Surgical were worth $769,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of ISRG. Mirador Capital Partners LP boosted its holdings in shares of Intuitive Surgical by 1.4% in the 3rd quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock valued at $1,732,000 after purchasing an additional 50 shares in the last quarter. Advisors Asset Management Inc. boosted its stake in Intuitive Surgical by 18.1% in the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock valued at $2,945,000 after buying an additional 1,129 shares in the last quarter. Consolidated Planning Corp boosted its stake in Intuitive Surgical by 17.4% in the third quarter. Consolidated Planning Corp now owns 8,099 shares of the medical equipment provider’s stock valued at $3,979,000 after buying an additional 1,198 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its position in Intuitive Surgical by 617.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock valued at $39,622,000 after acquiring an additional 76,649 shares during the last quarter. Finally, Swiss National Bank raised its stake in Intuitive Surgical by 0.3% during the third quarter. Swiss National Bank now owns 1,052,800 shares of the medical equipment provider’s stock worth $517,209,000 after acquiring an additional 3,400 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 0.5 %

Shares of Intuitive Surgical stock opened at $547.87 on Friday. The business has a 50-day moving average price of $504.73 and a two-hundred day moving average price of $463.54. Intuitive Surgical, Inc. has a 1-year low of $304.50 and a 1-year high of $552.00. The company has a market cap of $195.14 billion, a P/E ratio of 88.08, a PEG ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The business had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Equities research analysts forecast that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Royal Bank of Canada raised their price target on shares of Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a research note on Friday, October 18th. The Goldman Sachs Group set a $604.00 target price on shares of Intuitive Surgical in a research report on Friday, October 18th. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price target for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. Oppenheimer reiterated a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. Finally, Truist Financial boosted their price objective on Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $524.61.

Insider Transactions at Intuitive Surgical

In related news, EVP Robert Desantis sold 188 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total transaction of $90,655.48. Following the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,655,048.26. This represents a 3.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Gary Loeb sold 300 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $475.00, for a total value of $142,500.00. Following the completion of the sale, the general counsel now directly owns 1,595 shares of the company’s stock, valued at $757,625. The trade was a 15.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,935 shares of company stock valued at $26,305,169 in the last quarter. 0.90% of the stock is currently owned by company insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.